NTRK3 Fusion Positive

DrugDrug NameDrug Description
DB14723LarotrectinibLarotrectinib is an orally administered tropomyosin receptor kinase (Trk) inhibitor with demonstrated antineoplastic activity. Upon administration, larotrectinib binds to Trk, thereby preventing neurotrophin-Trk interaction and Trk activation, which results in both the induction of cellular apoptosis and the inhibition of cell growth in tumors that overexpress Trk. Trk, a receptor tyrosine kinase activated by neurotrophins, is mutated in a variety of cancer cell types and plays an important role in tumor cell growth and survival. Originally discovered by Array BioPharma, the agent was ultimately licensed to Loxo Oncology in 2013. Larotrectinib is another example of innovative new cancer therapy medications that target key, specific genetic biomarker drivers of cancer rather than particular types of tumors [L4847].
DrugDrug NamePhaseStatusCount
DB11791Capmatinib2Completed1
DB09063Ceritinib2Completed1
DB11986Entrectinib2Completed1
DB14723Larotrectinib2Not Yet Recruiting1
DB14723Larotrectinib2Recruiting1
DB08896Regorafenib2Completed1